Abiopharma

🔍 ELMS STEVE (Executive)

Company: ADMA BIOLOGICS, INC. (ADMA)

Report Date: 2026-02-09

Detailed Transactions and Holdings:

• Acquired 10,690 shares of Common Stock (Direct)
  Date: 2026-02-09 | Code: A | equity_swap_involved: 0 | shares_owned_after: 98,020.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-02-09 | Code: H | nature_of_ownership: See footnote | shares_owned_after: 2,031,730.00 | Footnotes: F3
• Acquired 17,730 shares of Stock Option (Right to Buy) at $16.37 per share (Derivative)
  Date: 2026-02-09 | Code: A | Expires: 2036-02-09 | equity_swap_involved: 0 | shares_owned_after: 17,730.00 | transaction_form_type: 4 | Footnotes: F4

Footnotes:

• F1: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date.
• F2: Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; (ii) 5,445 RSUs out of 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the Reporting Person's continued service as of such vesting date; and (iii) 81,885 shares of common stock owned by the Reporting Person.
• F3: These shares are owned by Aisling Capital II LP ("Aisling"), which is a fund that was established in 2007 with a 10-year life. Mr. Elms is Aisling's designee for nomination to the Board. As a Managing Member of Aisling Capital Partners, LLC ("Aisling Partners"), a control person of Aisling, and as a member of the investment committee of Aisling Capital Partners, LP ("Aisling GP"), Mr. Elms may be deemed to be the beneficial owner of shares of common stock owned of record by Aisling. Mr. Elms disclaims beneficial ownership of Aisling's investment in the Issuer and Aisling Partners' ownership of the Issuer's options, except to the extent of his pecuniary interest therein.
• F4: These options vest in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.